Boston Scientific (BSX) said Monday it agreed to acquire medical device company SoniVie.
Boston Scientific currently owns an equity stake of around 10 percent in SoniVie. The transaction consists of an upfront payment of $360 million for the remaining 90% stake and up to $180 million upon achievement of a regulatory milestone.
SoniVie's main product is the Tivus intravascular ultrasound system, an investigational technology designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension. The Tivus system is designed to help reduce activity in the kidney's renal nerves and serve as an alternative or adjunctive therapy to medications to help regulate blood pressure.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。